Poorly Differentiated Neuroendocrine Carcinoma of the Stomach: Understanding Your Pathology Report

Section Editor: David Driman MBChB FRCPC
November 11, 2026


Print this article

Poorly differentiated neuroendocrine carcinoma of the stomach is a rare, fast-growing type of stomach cancer. It starts from cells with features of neuroendocrine cells, which are hormone-producing cells found in the lining of the stomach. Pathologists divide this cancer into two types: small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma. Your report may also call it NEC, which is short for neuroendocrine carcinoma.

Poorly differentiated neuroendocrine carcinoma is very different from a well-differentiated neuroendocrine tumor of the stomach, which usually grows slowly. This article explains how poorly differentiated neuroendocrine carcinoma of the stomach is diagnosed, how it is staged, and what the other findings in your pathology report mean.

Who gets poorly differentiated neuroendocrine carcinoma of the stomach?

Poorly differentiated neuroendocrine carcinoma of the stomach is rare and makes up only about 1% of all stomach cancers. It is most often found in adults in their 60s and is much more common in men than in women.

What causes poorly differentiated neuroendocrine carcinoma of the stomach?

The cause of poorly differentiated neuroendocrine carcinoma of the stomach is not well understood. Unlike well-differentiated neuroendocrine tumors, it is not usually linked to high gastrin levels or atrophic gastritis. Many of these cancers share genetic changes with adenocarcinoma of the stomach, the most common type of stomach cancer. Some are found together with an adenocarcinoma in the same tumor.

What are the symptoms of poorly differentiated neuroendocrine carcinoma of the stomach?

The symptoms of poorly differentiated neuroendocrine carcinoma of the stomach are similar to those of other stomach cancers. Because this cancer grows quickly, symptoms often develop over weeks to months. Many people already have spread to the liver or other organs when the cancer is found.

  • Abdominal pain or indigestion. Pain or discomfort in the upper abdomen is one of the most common symptoms.
  • Weight loss and poor appetite. Many people lose weight without trying or feel full after eating only a small amount.
  • Nausea and vomiting. A large tumor can block food from passing out of the stomach.
  • Bleeding and anemia. The tumor can bleed, causing anemia, tiredness, black stools, or vomiting blood.

How is the diagnosis made?

The diagnosis of poorly differentiated neuroendocrine carcinoma of the stomach is usually made after a biopsy taken during an upper endoscopy. A pathologist examines the tissue under a microscope and uses immunohistochemistry to confirm that the cancer cells are neuroendocrine cells. If the tumor is later removed by surgery, the whole tumor and the nearby lymph nodes are examined to determine the stage.

Under the microscope, the cancer cells grow in solid sheets or large nests, and many cells are dividing. Areas of dead tumor tissue, called necrosis, are common. In small cell neuroendocrine carcinoma, the cells are small with very little cytoplasm and dark nuclei. In large cell neuroendocrine carcinoma, the cells are larger, with more cytoplasm and prominent nucleoli.

After the diagnosis, imaging such as a CT scan or PET scan is used to see whether the cancer has spread.

Immunohistochemistry

Immunohistochemistry is a test that uses antibodies to show which proteins are present in cells. For poorly differentiated neuroendocrine carcinoma of the stomach, it confirms that the cancer cells are neuroendocrine cells. It also helps separate this cancer from poorly differentiated adenocarcinoma, lymphoma, and other tumors that can look similar. Your report may describe some of the following results.

  • Synaptophysin and chromogranin. The cancer cells are usually positive for synaptophysin. Chromogranin is often weaker or present in only some cells.
  • INSM1. The cancer cells are usually positive for INSM1, another marker of neuroendocrine cells.
  • CD56. The cancer cells are often positive for CD56. This marker is less specific than synaptophysin and INSM1, so it supports the diagnosis but does not confirm it on its own.
  • Cytokeratins. Cancer cells are usually positive for cytokeratins, indicating a carcinoma.
  • Ki-67. Ki-67 shows the percentage of cancer cells that are dividing. In neuroendocrine carcinoma, Ki-67 is always above 20% and is often above 60%.
  • p53 and Rb. Some laboratories also test the cancer cells for p53 and the Rb protein. Abnormal results are common in neuroendocrine carcinoma and help separate it from a grade 3 well differentiated neuroendocrine tumor.

Not every laboratory performs eallof these tests, so your report may include only some

What are the different types of poorly differentiated neuroendocrine carcinoma?

The World Health Organization (WHO) classification (5th edition, 2019) recognizes two types of poorly differentiated neuroendocrine carcinoma, based on how the cells look under the microscope. A related tumor, described below, contains neuroendocrine carcinoma mixed with another type of cancer.

  • Small cell neuroendocrine carcinoma. The cancer cells in small cell neuroendocrine carcinoma are small, with very little cytoplasm and tightly packed nuclei. The cells often grow in tightly packed sheets with many dividing cells.
  • Large cell neuroendocrine carcinoma. The cancer cells are larger, with more cytoplasm and visible nucleoli. Large-cell and small-cell types behave similarly and are treated the same way.
  • Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN). A MiNEN contains both neuroendocrine carcinoma and another type of cancer, usually adenocarcinoma. Each part must make up at least 30% of the tumor, and your report may describe the percentage of each part.

Histologic grade

All poorly differentiated neuroendocrine carcinomas of the stomach are high grade, which means the cancer cells look very different from normal cells and divide quickly. Pathologists count more than 20 dividing cells, called mitotic figures, in an area of 2 square millimeters, and the Ki-67 index is above 20%. Because the grade is always high, some reports do not list a separate grade.

Depth of invasion

Depth of invasion describes how far poorly differentiated neuroendocrine carcinoma has grown into the stomach wall. The stomach wall has several layers, starting with the lamina propria and submucosa under the surface, then the thick muscularis propria, and finally the serosa on the outside. Deeper growth increases the risk of spread and helps determine tumor stage.

Lymphovascular invasion

Lymphovascular invasion means that cells from the neuroendocrine carcinoma were seen inside a blood vessel or lymphatic channel. Cancer cells can use these vessels to spread to lymph nodes, the liver, and other organs. Lymphovascular invasion is common in neuroendocrine carcinoma because the cancer grows quickly.

Perineural invasion

Perineural invasion means that cells from the neuroendocrine carcinoma were seen along or around a nerve. Cancer cells can use nerves to spread into nearby tissue. Perineural invasion is reported because it is linked with a higher chance that the cancer will come back.

Margins

A margin is the edge of the tissue that was cut to remove poorly differentiated neuroendocrine carcinoma of the stomach. For a surgical removal of part or all of the stomach, the pathologist checks the proximal margin, the distal margin, and the omental margins.

  • Negative margin. No cancer cells are seen at the cut edge, which means the cancer was likely removed completely.
  • Positive margin. Cancer cells are seen at the cut edge, which means some cancer may have been left behind. A positive margin increases the risk that the cancer will come back and may affect the treatment your doctors recommend.

Lymph nodes

Lymph nodes are removed with the stomach during surgery for poorly differentiated neuroendocrine carcinoma. The pathologist examines each lymph node under a microscope to look for cancer cells. Your report will give the number of lymph nodes examined and the number that contain cancer. Spread to lymph nodes is common in this cancer and helps determine the nodal stage.

Pathologic stage (pTNM)

Poorly differentiated neuroendocrine carcinoma of the stomach is staged the same way as other stomach cancers, using the AJCC staging system (8th edition). This differs from the system used for well-differentiated neuroendocrine tumors of the stomach. The stage is assigned only after the tumor has been removed by surgery.

Tumor stage (pT)

  • pT1a. The tumor has grown into the lamina propria or the thin muscle layer just below it, called the muscularis mucosae.
  • pT1b. The tumor has grown into the submucosa.
  • pT2. The tumor has grown into the muscularis propria.
  • pT3. The tumor has grown through the muscularis propria into the tissue just below the outer surface of the stomach.
  • pT4a. The tumor has grown through the serosa, the outer surface of the stomach.
  • pT4b. The tumor has grown into nearby organs or structures, such as the spleen, pancreas, liver, or colon.

Nodal stage (pN)

  • pN0. No cancer cells were found in the examined lymph nodes.
  • pN1. Cancer cells were found in 1 or 2 lymph nodes.
  • pN2. Cancer cells were found in 3 to 6 lymph nodes.
  • pN3a. Cancer cells were found in 7 to 15 lymph nodes.
  • pN3b. Cancer cells were found in 16 or more lymph nodes.

What is the prognosis?

The prognosis for a person with poorly differentiated neuroendocrine carcinoma of the stomach is generally poor, because most people are diagnosed after the cancer has spread. According to the European Neuroendocrine Tumor Society (ENETS), people whose cancer has spread to other organs live a median of about 11 to 12 months. This means about half of people live longer than this and about half live less.

The outlook is better when the cancer is found before it has spread and can be removed with surgery. In one large study, about 1 in 4 people with neuroendocrine carcinoma of the stomach were alive 5 years after the diagnosis. The most important factors are the stage, especially whether the cancer has spread to lymph nodes or other organs, and whether the whole tumor was removed.

What happens after the diagnosis?

Treatment for poorly differentiated neuroendocrine carcinoma of the stomach depends on whether the cancer has spread. The ENETS guidance published in 2023 describes the following approaches.

  • Cancer that has not spread. Surgery to remove part or all of the stomach and the nearby lymph nodes can help people whose cancer is limited to the stomach. Before surgery, careful imaging is done to make sure the cancer has not spread. Chemotherapy may also be given before or after surgery, because this cancer often comes back after surgery alone.
  • Cancer that has spread. The usual first treatment is chemotherapy with a platinum drug, such as carboplatin or cisplatin, combined with etoposide. If the cancer grows despite this treatment, a combination of irinotecan with a fluoropyrimidine drug is the most common next option.
  • Molecular testing and immunotherapy. Your oncologist may order genetic testing of the tumor to look for changes that could be treated with a targeted drug or a clinical trial. Immunotherapy plays only a small role for most people with this cancer.

Questions to ask your doctor

  • Is my cancer small-cell or large-cell neuroendocrine carcinoma?
  • Was any adenocarcinoma found in the tumor, and is it a MiNEN?
  • What was the Ki-67 index?
  • Has the cancer spread to lymph nodes, the liver, or other organs?
  • What is the stage of my cancer?
  • Were the margins negative?
  • Is surgery an option for me?
  • Will I need chemotherapy, and will it be given before or after surgery?
  • Should my tumor have genetic testing?
  • Are there clinical trials I could join?
  • How often will I need scans after treatment?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?